RT Journal Article
SR Electronic
T1 Using Whole Genome Sequences to Investigate Adenovirus Outbreaks, Including Five Deaths in a Haematopoietic Stem Cell Transplant Unit
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.26.20239111
DO 10.1101/2020.11.26.20239111
A1 Chloe E. Myers
A1 Charlotte J. Houldcroft
A1 Sunando Roy
A1 Ben K. Margetts
A1 Timothy Best
A1 Cristina Venturini
A1 José A. Guerra-Assunção
A1 Charlotte A. Williams
A1 Rachel Williams
A1 Helen Dunn
A1 John C. Hartley
A1 Kathryn J. Rolfe
A1 Judith Breuer
YR 2020
UL http://medrxiv.org/content/early/2020/11/30/2020.11.26.20239111.abstract
AB Background Human mastadenoviruses (HAdV) are associated with significant morbidity and mortality amongst the immunocompromised population. A recent surge in HAdV cases, including five deaths, amongst a haematopoietic stem cell transplant population led us to use whole genome sequencing (WGS) to investigate.Methods To gain a complete transmission picture, we compared outbreak and non-outbreak sequences (54 sequences from 37 patients) with GenBank sequences and our own database of previously sequenced HAdVs (132 sequences from 37 patients). An improved bait set for WGS was used. Maximum likelihood trees and pairwise differences were used to evaluate genotypic relationships paired with epidemiological data from routine Infection, Prevention and Control (IPC) activity.Results Nine monophyletic clusters were identified, seven of which were corroborated by epidemiological evidence and by comparison of single nucleotide polymorphisms. Two incomplete patient clusters were identified by IPC over the same time period. Of the five patients who died, one had a mixed HAdV infection and two were the source of transmission events.Conclusions The clinical consequences of unmitigated HAdV transmission events are high. Focusing on two high risk wards using WGS we identified six transmission events, over prolonged periods, that would have gone unnoticed using traditional polymerase chain reaction and epidemiology. Mixed infection is frequent (10% of patients), providing a sentinel source of recombination and superinfection. Immunosuppressed patients harbouring a high rate of HAdV positivity require comprehensive surveillance. As a consequence of these findings, HAdV WGS is being incorporated routinely into a clinical algorithm to prevent transmission and influence IPC policy in real-time.Summary Whole genome sequencing of adenovirus, direct from clinical samples, can be used to identify cryptic health care associated transmission events, and to resolve transmission suspected by traditional epidemiology. It can also identify mixed genotype infections in immunocompromised patient populations.Competing Interest StatementAgilent license the adenovirus bait designs used in this paper.Funding StatementThis work was supported by the National Institute for Health Research Biomedical Research Centre at Great Ormond Street Hospital for Children NHS Foundation Trust and University College London. Sequencing of 121 samples, making up the pilot study, were funded by an Action Medical Research Grant [grant number GN2424] [CJH]. Sequencing of subsequent samples were funded by JB who receives funding from the National Institute of Health Research University College London / University College London Hospitals NHS Foundation Trust Biomedical Research Centre. The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication. Potential conflict of interest: Agilent license our adenovirus bait designs.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Use of these samples for research was approved by The National Research Ethics Service Committee London Fulham (reference: 17/LO/1530).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesGenome sequences will be assigned GenBank accessions upon publication.